Press Releases April 20, 2026 04:01 PM

Carlyle Credit Income Fund Schedules Second Quarter Financial Results and Investor Conference Call

Carlyle Credit Income Fund Announces Q2 2026 Financial Results Release and Investor Call

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
CCIF

Carlyle Credit Income Fund (NYSE: CCIF) announced it will release its second quarter 2026 financial results on May 19, 2026, with a follow-up investor conference call scheduled for May 20. The fund focuses on investing in equity and junior debt tranches of CLOs backed primarily by U.S. senior secured loans across diverse industry sectors.

Carlyle Credit Income Fund Schedules Second Quarter Financial Results and Investor Conference Call
CCIF
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Carlyle Credit Income Fund focuses on CLO investments backed by U.S. senior secured loans across various sectors.
  • The second quarter 2026 financial results will be released after market close on May 19, with an investor call on May 20.
  • The fund benefits from management by Carlyle Global Credit Investment Management, leveraging Carlyle's scale as a leading CLO manager.

NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Carlyle Credit Income Fund (“we,” “us,” “our,” “CCIF” or the “Fund”) (NYSE: CCIF) announced today that it will release financial results after market close on Tuesday, May 19, 2026, for its second quarter of 2026. CCIF will host a conference call at 10:00 a.m. EST on Wednesday, May 20, 2026, to discuss the results.

The conference call will be available via public webcast via a link on Carlyle Credit Income Fund’s website at www.carlylecreditincomefund.com and will also be available on the website soon after the call’s completion.

About Carlyle Credit Income Fund

Carlyle Credit Income Fund (NYSE: CCIF) is an externally managed closed-end fund focused on investing in primarily equity and junior debt tranches of collateralized loan obligations ("CLOs"). The CLOs are collateralized by a portfolio consisting primarily of U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors. CCIF is externally managed by Carlyle Global Credit Investment Management L.L.C. (“CGCIM”), an SEC-registered investment adviser and wholly owned subsidiary of Carlyle. CCIF draws upon the significant scale and resources of Carlyle as one of the world's largest CLO managers.

Web: www.carlylecreditincomefund.com

About Carlyle

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit and Carlyle AlpInvest. With $477 billion of assets under management as of December 31, 2025, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. Carlyle employs more than 2,500 people in 27 offices across four continents. Further information is available at www.carlyle.com. Follow Carlyle on X @OneCarlyle and on LinkedIn at The Carlyle Group.

Contacts:

Investors:Media:Joseph CastillaKristen Ashton+1 (866) 277-8243
[email protected]+1 (212) 813-4763
[email protected]

Risks

  • Performance depends on credit quality and performance of underlying U.S. senior secured loans within CLO portfolios, which can be affected by economic conditions affecting multiple sectors.
  • Market volatility and credit market dynamics may impact CLO valuations and distributions.
  • Regulatory and interest rate changes could affect the CLO market and fund's returns.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026